Chemistry. Chemicals were purchased from Sigma-Aldrich, Alfa Aesar, and TCI Chemicals. Unless otherwise stated, all chemicals were used without further purification. Thin layer chromatography (TLC) was performed using plates from Merck (silica gel 60 F254). Column chromatography was performed with 1:30 Merck silica gel 60 Å (63-200 μm) as the stationary phase. Flash chromatographic separations were performed on a Biotage SP1 purification system using flash cartridges pre-packed with KP-Sil 32−63 μm, 60 Å silica gel. ^{1}H NMR spectra were recorded on a Varian Mercury-VX spectrometer (300 MHz) or an Agilent NMR spectrometer (500 MHz). All chemical shift values are reported in ppm (δ). For enantiomeric pairs, NMR spectra of both enantiomers were recorded; however, only the NMR spectrum of the (*R*)-enantiomer is reported in the experimental section. Recording of mass spectra was performed on an HP6890-5973 MSD gas chromatograph/mass spectrometer; only significant *m/z* peaks, with their percentage of relative intensity in parentheses are reported. HRMS-ESI analyses were performed on a Bruker Daltonics MicrOTOF-Q II mass spectrometer, mass range 50-800 *m/z*, electrospray ion source in positive or negative ion mode. All spectra were in accordance with the assigned structures. The purity of the target compounds listed in Table 1 and Table 2 was assessed by RP-HPLC and combustion analysis. All compounds showed ≥ 98% purity. RP-HPLC analysis was performed on an Agilent 1260 Infinity Binary LC System equipped with a diode array detector using a Phenomenex Gemini C-18 column (250 x 4.6 mm, 5 μm particle size). All target compounds were eluted with CH_3OH/H_2O, 8:2 (v/v) at a flow rate of 1 mL/min. Elemental analyses (C,H,N) of the target compounds were performed on an Eurovector Euro EA 3000 analyzer. Analyses indicated by the symbols of the elements were within ± 0.4 % of the theoretical values. Enantiomeric purity of the target compounds (*R*)- and (*S*)-**24-27** was assessed by chiral HPLC analysis on a Perkin-Elmer series 200 LC instrument using a Daicel ChiralCel OD column (250 mm × 4.6 mm, 5 μm particle size) and equipped with a Perkin-Elmer 785A UV/VIS detector setting λ= 230 nm. The compounds were eluted with *n*-hexane/EtOH, 4:1, v/v at a flow rate of 0.8 mL/min. All compounds showed enantiomeric excesses ≥ 98%.

3-[1-(Aminomethyl)cyclopropyl]phenol (13). To a cooled solution of [1-(3-methoxyphenyl)cyclopropyl]methanamine (**11**) (0.51 g, 2.9 mmol) in anhydrous CH_2Cl_2 (10 mL) 1.0 M boron tribromide in CH_2Cl_2 (5 mL, 5.1 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 4 h and neutralized with 10% aqueous NH_4OH. The aqueous phase was extracted with CH_2Cl_2 (2 × 20 mL). The combined organic layers were dried (Na_2SO_4) and concentrated under reduced pressure to give the target compound as a pale yellow solid (0.33 g, 70% yield), which was used in the next step without further purification. ^{1}H NMR (300 MHz, $CDCl_3$): δ= 0.72–0.81 (m, 4H), 1.35 (br s, 2H), 2.74 (s, 2H), 5.35 (br s, 1H), 6.84-6.88 (m, 3H), 7.26 ppm (m, 1H). GC/MS: *m/z* 163 (M^+, 5), 133 (35), 105 (100).

4-[1-(Aminomethyl)cyclopropyl]phenol (14). Prepared as described above for derivative **13** starting from the [1-(3-methoxyphenyl)cyclopropyl]methanamine (**12**) (0.31 g; 65% yield). ^{1}H NMR (300 MHz, $CDCl_3$): δ= 0.74–0.83 (m, 4H), 1.35 (br s, 2H), 2.76 (s, 2H), 5.35 (br s, 1H), 6.79-6.82 (m, 2H), 7.16-7.19 ppm (m, 2H). GC/MS: *m/z* 163 (M^+, 7), 133 (45), 105 (100).

General Procedure for the Synthesis of Boc-protected Derivatives (*R*)- and (*S*)-17-18, (2*R*)-30 and (2*S*)- 32,33. *N,N'*-Carbonyldiimidazole (1.1 mmol) was added to a solution of (*R*)- or (*S*)-Boc-protected amino acid (1.0 mmol), in anhydrous THF (10 mL) under N_2. The reaction mixture was stirred at room temperature overnight, then a solution of the appropriate amine (1.0 mmol) in anhydrous THF was added. The reaction mixture was stirred at room temperature for 6 h. After removal of the solvent *in vacuo*, the residue was partitioned between EtOAc (20 mL) and H_2O (2 × 20 mL). The aqueous layer was separated and extracted twice with EtOAc (20 mL). The collected organic layers were dried (Na_2SO_4) and evaporated *in vacuo*. The crude residue was chromatographed as detailed below to give pure target compound as a white solid.

(*R*)-*tert*-Butyl {3-(4-cyanophenyl)-1-[[[1-(3-hydroxyphenyl)cyclopropyl]methyl]amino]-1-oxopropan-2-yl}carbamate ((*R*)-17). Eluted with $CHCl_3$/AcOEt 8:2. 88% Yield. ^{1}H NMR (500 MHz, $CDCl_3$): δ= 0.76–0.85 (m, 4H), 1.38 (s, 9H), 2.10 (br s, 1H, D_2O exchanged), 2.96 (dd, 1H, *J*= 13.7 and 6.9 Hz), 3.08 (dd, 1H, *J*= 13.7 and 6.9 Hz), 3.28–3.31 (m, 1H), 3.36 (dd, 1H, *J*= 13.7 and 5.4 Hz), 4.24–4.32 (m, 1H), 5.12 (br d, 1H), 6.00 (br t, 1H), 6.66–6.71 (m, 3H), 7.12 (t, 1H, *J*= 7.8 Hz), 7.22 (d, 2H, *J*= 8.3 Hz), 7.52 ppm (d, 2H, *J*= 8.3 Hz). ESI^+/MS *m/z* 458 $(M+Na)^+$, ESI^+/MS/MS *m/z* 358 (100).

(*S*)-*tert*-Butyl {3-(4-cyanophenyl)-1-[[[1-(3-hydroxyphenyl)cyclopropyl]methyl]amino]-1-oxopropan-2-yl}carbamate ((*S*)-17). Eluted with $CHCl_3$/AcOEt 8:2. 87% Yield. ESI^+/MS *m/z* 458 $(M+Na)^+$, ESI^+/MS/MS *m/z* 358 (100).

(*R*)-*tert*-Butyl {3-(4-cyanophenyl)-1-[[[1-(4-hydroxyphenyl)cyclopropyl]methyl]amino]-1-oxopropan-2-yl}carbamate ((*R*)-18). Eluted with $CHCl_3$/AcOEt 8:2. 45% Yield. ^{1}H NMR (500 MHz, $CDCl_3$): δ= 0.76–0.85 (m, 4H), 1.37 (s, 9H), 1.91 (br s, 1H, D_2O exchanged), 2.96 (dd, 1H, *J*= 13.7, 6.9 Hz), 3.07 (dd, 1H, *J*= 13.7, 6.9 Hz), 3.28-3.30 (m, 1H), 3.36 (dd, 1H, *J*= 13.7, 5.3 Hz), 4.30–4.38 (m, 1H), 5.18 (br d, 1H), 6.10 (br t, 1H), 6.65-6.71 (m, 3H), 7.12 (t, 1H, *J*= 7.8 Hz), 7.21 (d, 2H, *J*= 7.8 Hz), 7.50 ppm (d, 2H, *J*= 8.3 Hz). ESI^+/MS *m/z* 458 $(M+Na)^+$, ESI^+/MS/MS *m/z* 358 (100).

(*S*)- *tert*-Butyl {3-(4-cyanophenyl)-1-[[[1-(4-hydroxyphenyl)cyclopropyl]methyl]amino]-1-oxopropan-2-yl}carbamate ((*S*)-18). Eluted with $CHCl_3$/AcOEt 8:2. 51% Yield. ESI^+/MS *m/z* 458 $(M+Na)^+$, ESI^+/MS/MS *m/z* 358 (100).

(2*R*)-*tert*-Butyl [1-oxo-1-[(2-oxoazepan-3-yl)amino]-3-phenylpropan-2-yl]carbamate ((2*R*)-30). Eluted with $CHCl_3$/AcOEt 7:3. 47% Yield. ^{1}H NMR (500 MHz, $CDCl_3$): δ= 1.24–1.45 (m + s, 11H), 1.77–1.85 (m, 2H), 1.93–2.07 (m, 2H), 3.05–3.09 (m, 2H), 3.22–3.30 (m, 2H), 4.42–4.45 (m, 2H),

5.00–5.10 (m, 1H), 6.07–6.13 (br d, 1H), 7.12 (br s, 1H), 7.17–7.24 (m, 3H), 7.26-7.30 ppm (m, 2H). ESI^+/MS *m/z* 398 $(M+Na)^+$, ESI^+/MS/MS *m/z* 129 (100).

(2*S*)-*tert*-Butyl [1-oxo-1-[(2-oxoazepan-3-yl)amino]-3-phenylpropan-2-yl]carbamate ((2*S*)-32). Eluted with $CHCl_3$/AcOEt 7:3. 72% Yield. ^1H NMR (500 MHz, $CDCl_3$): δ= 1.24–1.45 (m + s, 11H), 1.75–1.83 (m, 2H), 1.93–2.07 (m, 2H), 3.04–3.07 (m, 2H), 3.21–3.33 (m, 2H), 4.42–4.45 (m, 2H), 5.00–5.10 (m, 1H), 6.07–6.13 (br d, 1H), 7.12 (br s, 1H), 7.17–7.24 (m, 3H), 7.26-7.30 ppm (m, 2H). ESI^+/MS *m/z* 398 $(M+Na)^+$, ESI^+/MS/MS *m/z* 129 (100).

(2*S*)-*tert*-Butyl {3-(4-hydroxyphenyl)-1-oxo-1-[(2-oxoazepan-3-yl)amino]propan-2-yl}carbamate ((2*S*)-33). Eluted with $CHCl_3$/MeOH 19:1. 72% Yield. ^1H NMR (500 MHz, $CDCl_3$): δ= 1.28–1.45 (m + s, 11H), 1.76–1.82 (m, 3H, 1H D_2O exchanged), 1.90–2.07 (m, 2H), 2.92–3.00 (m, 2H), 3.21–3.27 (m, 2H), 4.38–4.46 (m, 2H), 5.14–5.30 (m, 1H), 6.36 (br s, 2H), 6.72 (d, 2H, *J*= 8.3 Hz), 6.99–7.05 (m, 2H), 7.15–7.16 ppm (m, 1H). ESI^+/MS *m/z* 414 $(M+Na)^+$, ESI^+/MS/MS *m/z* 314 (100).

General Procedure for the Synthesis of Amines (*R*)- and (*S*)-21-22, (2*R*)-34 and (2*S*)-36,37. To a solution of Boc-protected derivatives (*R*)- and (*S*)-**17-18**, (2*R*)-**30,31** and (2*S*)-**32,33** (0.46 mmol) in 1,4-dioxane (10 mL) 3N hydrochloric acid (5 mL) was added. The reaction mixture was stirred at room temperature for 24 h and basified with 5% aqueous NaOH. The separated aqueous phase was extracted with EtOAc (2 × 20 mL). The combined organic layers were dried (Na_2SO_4) and concentrated *in vacuo* to afford pure target amine (colorless oil) in quantitative yield.

(*R*)-2-Amino-3-(4-cyanophenyl)-*N*-[[1-(3-hydroxyphenyl)cyclopropyl]methyl]propanamide ((*R*)-21). ^1H NMR (500 MHZ, $CDCl_3$): δ= 0.77–0.89 (m, 4H), 1.58 (br s, 2H, D_2O exchanged), 2.20 (br s, 1H, D_2O exchanged), 2.76 (dd, 1H, *J*= 13.7, 8.3 Hz), 3.16 (dd, 1H, *J*= 13.7 Hz, 4.4 Hz), 3.35

(dd, 1H, *J*= 13.7, 5.3 Hz), 3.49 (dd, 1H, *J*= 13.7, 5.3 Hz), 3.57 (dd, 1H, *J*= 8.3, 4.4 Hz), 6.69-6.72 (m, 2H), 6.79 (br s, 1H), 7.13 (t, 1H, *J*= 7.8 Hz), 7.23-7.26 (m, 2H), 7.29 (br t, 1H), 7.54 ppm (d, 2H, *J*= 8.3 Hz). ESI^+/MS *m/z* 358 $(M+Na)^+$, ESI^+MS/MS *m/z* 188 (57), 171 (39), 109 (100).

(*S*)-2-Amino-3-(4-cyanophenyl)-*N*-[[1-(3-hydroxyphenyl)cyclopropyl]methyl]propanamide ((*S*)-21). ESI^+/MS *m/z* 358 $(M+Na)^+$, ESI^+MS/MS *m/z* 188 (57), 171 (40), 109 (100).

(*R*)-2-Amino-3-(4-cyanophenyl)-*N*-[[1-(4-hydroxyphenyl)cyclopropyl]methyl]propanamide ((*R*)-22). ^1H NMR (500 MHz, $CDCl_3$): δ= 0.77–0.83 (m, 4H), 1.57 (br s, 2H, D_2O exchanged), 2.15 (br s, 1H, D_2O exchanged), 2.73 (dd, 1H, *J*= 13.7, 8.3 Hz), 3.13 (dd, 1H, *J*= 13.7 Hz, 4.4 Hz), 3.37 (dd, 1H, *J*= 13.7, 5.8 Hz), 3.42 (dd, 1H, *J*= 13.7, 5.8 Hz), 3.55 (dd, 1H, *J*= 8.3, 4.4 Hz), 6.72 (d, 2H, *J*= 8.8 Hz), 7.08 (d, 2H, *J*= 8.8 Hz), 7.23 (d, 2H, *J*= 8.3 Hz), 7.29 (br t, 1H), 7.53 ppm (d, 2H, *J*= 8.3 Hz). ESI^-/MS *m/z* 334 $(M-H)^-$, ESI^-MS/MS *m/z* 116 (100), 133 (10), 188 (11).

(*S*)- 2-Amino-3-(4-cyanophenyl)-*N*-[[1-(4-hydroxyphenyl)cyclopropyl]methyl]propanamide ((*S*)-22). ESI/MS *m/z* 334 $(M-H)^-$, ESI-MS/MS *m/z* 116 (100), 160 (56), 188 (4).

(2*R*)-2-Amino-*N*-(2-oxoazepan-3-yl)-3-phenylpropanamide ((2*R*)-34). ^1H NMR (500 MHz, $CDCl_3$): δ= 1.36–1.53 (m, 2H), 1.60 (br s, 2H, D_2O exchanged), 1.80–1.90 (m, 2H), 2.0–2.05 (m, 2H), 2.67–2.75 (m, 1H), 3.21–3.35 (m, 3H), 3.61 (td, 1H, *J*= 9.3, 4.4 Hz), 4.51–4.56 (m, 1H), 6.07 (br t, 1H), 7.21–7.25 (m, 3H), 7.30–7.32 (m, 2H), 8.10–8.30 ppm (m, 1H). ESI^+/MS *m/z* 298 $(M+Na)^+$, ESI^+MS/MS *m/z* 84 (100), 120 (46), 129 (38).

(2*S*)-2-Amino-*N*-(2-oxoazepan-3-yl)-3-phenylpropanamide ((2*S*)-36). ^1H NMR (500 MHz, $CDCl_3$): δ= 1.36–1.52 (m, 2H), 1.53 (br s, 2H, D_2O exchanged), 1.79–1.90 (m, 2H), 2.0–2.05 (m, 2H), 2.67–2.75 (m, 1H), 3.21–3.35 (m, 3H), 3.59–3.63 (m, 1H), 4.51–4.56 (m, 1H), 6.09 (br s, 1H), 7.21–7.26 (m, 3H), 7.29–7.32 (m, 2H), 8.12–8.30 ppm (m, 1H). ESI^+/MS *m/z* 298 $(M+Na)^+$, ESI^+MS/MS *m/z* 84 (100), 120 (46), 129 (38).

(2*S*)-2-Amino-3-(4-hydroxyphenyl)-*N*-(2-oxoazepan-3-yl)propanamide ((2*S*)-37). ^{1}H NMR (500 MHz, CD_3OD): δ= 1.22–1.55 (m, 2H), 1.68–2.05 (m, 4H), 2.68–2.75 (m, 1H), 2.85–2.98 (m, 1H), 3.16–3.31 (m, 2H), 3.51–3.58 (m, 1H), 4.45–4.60 (m, 1H), 6.72 (d, 2H, *J*= 8.3 Hz), 7.02-7.07 ppm (m, 2H). ESI^-/MS *m/z* 314 $(M+Na)^+$, ESI^+MS/MS *m/z* 84 (100), 120 (49).

General Procedure for the Synthesis of the Compounds (*R*)- and (*S*)-23,25-27, (2*R*)-38,39,46 and (2*S*)-40,41,47. To a solution of the amine (*R*)- and (*S*)-**19-22,** (2*R*)-**34,35** and (2*S*)-**36,37** (1.0 mmol) in anhydrous THF, a solution of the appropriate 3- or 4-substitued phenylisocyanate (1.2 mmol) in the same solvent (10 mL) was added and the reaction mixture was stirred at room temperature overnight. After removing the solvent *in vacuo*, the residue was dissolved in $CHCl_3$ (20 mL) and washed with H_2O (2 × 20 mL). The separated organic layer was dried over Na_2SO_4 and concentrated under reduced pressure. The crude residue was chromatographed as detailed below. When necessary, the obtained solid was further purified by crystallization from MeOH to give the pure target compound.

(*S*)-3-(4-Cyanophenyl)-2-[3-(4-methoxyphenyl)ureido]-*N*-[(1-phenylcyclopropyl)methyl]propanamide ((*S*)-23). Eluted with $CHCl_3$/AcOEt 8:2. 49% Yield. ESI^+/MS *m/z* 491 $(M+Na)^+$, ESI^+/MS/MS *m/z* 491 (100), 342 (28).

(*S*)-3-(4-Hydroxyphenyl)-2-[3-(4-methoxyphenyl)ureido]-*N*-[(1-phenylcyclopropyl)methyl]propanamide ((*S*)-25). Eluted with $CHCl_3$/MeOH 19:1. 40% Yield. ESI^+/MS *m/z* 460 $(M+H)^+$, ESI^+/MS/MS *m/z* 460 (5), 136 (100). Anal. calcd for $C_{27}H_{29}N_3O_4$: C 70.57, H 6.36, N 9.14, found: C 70.39, H 6.23, N 9.34

(*R*)-3-(4-Cyanophenyl)-*N*-((1-(3-hydroxyphenyl)cyclopropyl)methyl)-2-(3-(4-methoxyphenyl)ureido)propanamide ((*R*)-26). Eluted with $CHCl_3$/AcOEt 1:1. 12% Yield. ^{1}H

NMR (500 MHz, [D6]DMSO): δ= 0.69–0.71 (m, 1H), 0.77–0.79 (m, 1H), 0.82–0.85 (m, 2H), 2.76 (dd, 1H, *J*= 13.7, 7.8 Hz), 2.95 (dd, 1H, *J*= 13.7, 4.9 Hz), 3.10 (dd, 1H, *J*= 13.7, 4.4 Hz), 3.49 (dd, 1H, *J*= 13.7, 6.5 Hz), 3.66 (s, 3H), 4.49–4.54 (m, 1H), 6.16 (d, 1H, *J*= 8.3 Hz), 6.56 (d, 1H, *J*= 8.3 Hz), 6.65–6.68 (m, 2H), 6.77 (d, 2H, *J*= 8.8 Hz), 7.02 (t, 1H, *J*= 7.8 Hz), 7.17-7.22 (m, 4H), 7.66 (d, 2H, *J*= 8.3 Hz), 8.13(br t, 1H), 8.41 (s, 1H), 9.23 ppm (s, 1H). ESI/MS *m/z* 483 $(M-H)^-$, ESI-MS/MS *m/z* 116 (11), 188 (27), 317 (100). Anal. calcd for $C_{28}H_{28}N_4O_4$: C 69.41, H 5.82, N 11.56, found: C 69.54, H 5.84, N 11.34

(*S*)-3-(4-Cyanophenyl)-*N*-((1-(3-hydroxyphenyl)cyclopropyl)methyl)-2-(3-(4-methoxyphenyl)ureido)propanamide ((*S*)-26). Eluted with $CHCl_3$/AcOEt 1:1. 15% Yield. ESI/MS *m/z* 483 $(M-H)^-$, ESI-MS/MS *m/z* 116 (11), 188 (27), 317 (100). Anal. calcd for $C_{28}H_{28}N_4O_4$: C 69.41, H 5.82, N 11.56, found: C 69.33, H 5.94, N 11.34

(*R*)-3-(4-Cyanophenyl)-*N*-[[1-(4-hydroxyphenyl)cyclopropyl]methyl]-2-[3-(4-methoxyphenyl)ureido]propanamide ((*R*)-27). Eluted with $CHCl_3$/AcOEt 1:1. 17% Yield. ^1H NMR (500 MHz, [D6]DMSO): δ= 0.69–0.71 (m, 1H), 0.77–0.79 (m, 1H), 0.82–0.85 (m, 2H), 2.75 (dd, 1H, *J*= 13.7, 7.8 Hz), 2.93 (dd, 1H, *J*= 13.7, 4.9 Hz), 3.05 (dd, 1H, *J*= 13.7, 4.9 Hz), 3.42 (dd, 1H, *J*= 13.7, 6.4 Hz), 3.66 (s, 3H), 4.49–4.51 (m, 1H), 6.19 (d, 1H, *J*= 8.2 Hz), 6.62 (d, 2H, *J*= 8.8 Hz), 6.76 (d, 2H, *J*= 8.8 Hz), 7.05 (d, 2H, *J*= 8.3 Hz), 7.19 (d, 4H, *J*= 7.9 Hz), 7.66 (d, 2H, *J*= 8.3 Hz), 8.07 (br t, 1H), 8.44 (s, 1H), 9.16 ppm (s, 1H). ESI/MS *m/z* 483 $(M-H)^-$, ESI-MS/MS *m/z* 188 (26), 317 (100). Anal. calcd for $C_{28}H_{28}N_4O_4$: C 69.41, H 5.82, N 11.56, found: C 69.52, H 5.76, N 11.54

(*S*)-3-(4-Cyanophenyl)-*N*-[[1-(4-hydroxyphenyl)cyclopropyl]methyl]-2-[3-(4-methoxyphenyl)ureido]propanamide ((*S*)-27). Eluted with $CHCl_3$/AcOEt 1:1. 29% Yield. ESI/MS *m/z* 483 $(M-H)^-$, ESI-MS/MS *m/z* 116 (55), 288 (15), 317 (100). Anal. calcd for $C_{28}H_{28}N_4O_4$: C 69.41, H 5.82, N 11.56, found: C 69.62, H 5.69, N 11.62

(2*R*)-2-[3-(4-Methoxyphenyl)ureido]-*N*-(2-oxoazepan-3-yl)-3-phenylpropanamide ((2*R*)-38). Eluted with $CHCl_3$/MeOH 98:2. 54% Yield. ^{1}H NMR (500 MHz, [D6]DMSO): δ= 1.15–1.22 (m, 1H), 1.29–1.40 (m, 1H), 1.58–1.88 (m, 4H), 2.77–2.83 (m, 1H), 2.96 (dd, 1H, *J*= 13.7, 5.4 Hz), 3.02–3.06 (m, 1H), 3.12–3.20 (m, 1H), 3.66 (s, 3H), 4.34–4.38 (m, 1H), 4.46–4.55 (m, 1H), 6.21–6.27 (m, 1H), 6.76 (d, 2H, *J*= 8.8 Hz), 7.15–7.26 (m, 7H), 7.83 (br s, 1H), 7.97–8.05 (m, 1H), 8.47 ppm (d, 1H, *J*= 6.4 Hz). ESI^+/MS *m/z* 447 $(M+Na)^+$, ESI^+/MS/MS *m/z* 447 (100), 324 (26), 298 (67).

(2*R*)-2-[3-(3-Methoxyphenyl)ureido]-*N*-(2-oxoazepan-3-yl)-3-phenylpropanamide ((2*R*)-39). Eluted with $CHCl_3$/AcOEt 8:2. 85% Yield. ^{1}H NMR (500 MHz, [D6]DMSO): δ= 1.15–1.24 (m, 1H), 1.27–1.41 (m, 1H), 1.59–1.88 (m, 4H), 2.78–2.84 (m, 1H), 2.96 (dd, 1H, *J*= 13.7, 5.4 Hz), 3.01–3.07 (m, 1H), 3.12–3.20 (m, 1H), 3.67 (s, 3H), 4.34–4.39 (m, 1H), 4.49–4.57 (m, 1H), 6.29–6.36 (m, 1H), 6.44 (dd, 1H, *J*= 8.3, 2.4 Hz), 6.77 (d, 1H, *J*= 7.8 Hz), 7.06–7.09 (m, 2H), 7.16–7.18 (m, 1H), 7.22–7.26 (m, 4H), 7.81–7.83 (m, 1H), 8.00–8.09 (m, 1H), 8.67 ppm (br d, 1H). ESI^+/MS *m/z* 447 $(M+Na)^+$, ESI^+/MS/MS *m/z* 447 (100), 324 (62), 298 (54).

(2*S*)-2-[3-(4-Methoxyphenyl)ureido]-*N*-(2-oxoazepan-3-yl)-3-phenylpropanamide ((2*S*)-40). Eluted with $CHCl_3$/MeOH 98:2. 32% Yield. ^{1}H NMR (500 MHz, [D6]DMSO): δ= 1.15–1.26 (m, 1H), 1.28–1.39 (m, 1H), 1.55–1.88 (m, 4H), 2.77–2.83 (m, 1H), 2.95 (dd, 1H, *J*= 13.7, 5.4 Hz), 3.02–3.06 (m, 1H), 3.11–3.20 (m, 1H), 3.66 (s, 3H), 4.33–4.37 (m, 1H), 4.46–4.54 (m, 1H), 6.25–6.31 (m, 1H), 6.76 (d, 2H, *J*= 8.8 Hz), 7.15–7.26 (m, 7H), 7.82 (br s, 1H), 7.96–8.05 (m, 1H), 8.50 ppm (d, 1H, *J*= 8.3 Hz). ESI^+/MS *m/z* 447 $(M+Na)^+$, ESI^+/MS/MS *m/z* 447 (100), 324 (30), 298 (66).

(2*S*)-2-[3-(3-Methoxyphenyl)ureido]-*N*-(2-oxoazepan-3-yl)-3-phenylpropanamide ((2*S*)-41). Eluted with $CHCl_3$/AcOEt 8:2. 82% Yield. ^{1}H NMR (500 MHz, [D6]DMSO): δ= 1.15–1.24 (m, 1H), 1.27–1.41 (m, 1H), 1.58–1.88 (m, 4H), 2.78–2.84 (m, 1H), 2.96 (dd, 1H, *J*= 13.7, 5.4 Hz), 3.01–3.07 (m, 1H), 3.12–3.19 (m, 1H), 3.66 (s, 3H), 4.34–4.38 (m, 1H), 4.49–4.57 (m, 1H), 6.28–6.36 (m, 1H),

6.44 (dd, 1H, *J*= 8.3, 2.4 Hz), 6.77 (d, 1H, *J*= 7.8 Hz), 7.05–7.09 (m, 2H), 7.15–7.18 (m, 1H), 7.21–7.26 (m, 4H), 7.79–7.83 (m, 1H), 7.98–8.08 (m, 1H), 8.66 ppm (br d, 1H). ESI^+/MS *m/z* 447 $(M+Na)^+$, ESI^+/MS/MS *m/z* 447 (100), 324 (65), 298 (81).

(2*S*)-2-[3-(4-Bromophenyl)ureido]-3-(4-hydroxyphenyl)-*N*-(2-oxoazepan-3-yl)propanamide ((2*S*)-47). Eluted with $CHCl_3$/MeOH 98:2. 22% Yield. ^1H NMR (500 MHz, [D6]DMSO): δ= 1.12–1.39 (m, 2H), 1.56–1.87 (m, 4H), 2.67–2.73 (m, 1H); 2.81–2.93 (m, 1H), 3.01–3.05 (m, 1H), 3.11–3.20 (m, 1H), 4.33–4.39 (m, 1H), 4.40–4.47 (m, 1H), 6.28–6.36 (m, 1H), 6.62 (d, 2H, *J*= 8.3 Hz), 7.00 (dd, 2H, *J*= 8.8, 3.4 Hz), 7.29 (dd, 2H, *J*= 8.8, 1.5 Hz), 7.35 (d, 2H, *J*= 8.8 Hz), 7.79–7.83 (m, 1H), 7.92–8.01 (m, 1H), 8.84 (d, 1H, *J*= 10.3 Hz), 9.15 ppm (br s, 1H). ESI^+/MS *m/z* 511 $(M+Na)^+$, ESI^+/MS/MS *m/z* 340 (22), 314 (100). Anal. calcd for $C_{22}H_{25}BrN_4O_4$: C 54.00, H 5.15, N 11.46, found: C 54.32, H 5.04, N 11.54.

General Procedure for the Synthesis of the Final Compounds (*S*)-24, (*2R*)-42,43 and (2*S*)-44,45. To a cooled solution of the methoxy derivatives (*S*)-**23**, (2*R*)-**38,39** and (2*S*)-**40,41** (2.0 mmol) in anhydrous CH_2Cl_2 (10 mL), 1.0 M boron tribromide in CH_2Cl_2 (3.45 mL, 3.45 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 4 h and basified with 10% aqueous NH_4OH. The separated aqueous phase was extracted with CH_2Cl_2 (2 × 20 mL). The combined organic layers were dried (Na_2SO_4) and concentrated under reduced pressure. The crude residue was chromatographed as detailed below to give the target compound as solid, which was further purified by crystallization from MeOH.

(*S*)-3-(4-Cyanophenyl)-2-[3-(4-hydroxyphenyl)ureido]-*N*-[(1-phenylcyclopropyl)methyl]propanamide ((*S*)-24). Eluted with $CHCl_3$/MeOH 98:2. 8% Yield. ESI^+/MS *m/z* 455 $(M+H)^+$, ESI^+/MS/MS *m/z* 145 (100), 131 (65). Anal. calcd for $C_{27}H_{26}N_4O_3$: C 71.35, H 5.77, N 12.33, found: C 71.32, H 5.62, N 12.56.

(2*R*)-2-[3-(4-Hydroxyphenyl)ureido]-*N*-(2-oxoazepan-3-yl)-3-phenylpropanamide ((2*R*)-42). Eluted with $CHCl_3$/MeOH 19:1. 26% Yield. ^{1}H NMR (500 MHz, [D6]DMSO): δ= 1.15–1.28 (m, 1H), 1.31–1.39 (m, 1H), 1.55–1.88 (m, 4H), 2.77–2.83 (m, 1H), 3.03 (dd, 2H, *J*= 13.7, 4.4 Hz), 3.11–3.20 (m, 1H), 4.34–4.37 (m, 1H), 4.45–4.21 (m, 1H), 6.14 (d, 1H, *J*= 7.8 Hz), 6.59 (d, 2H, *J*= 8.8 Hz), 7.04–7.08 (m, 2H), 7.15–7.18 (m, 1H), 7.21–7.26 (m, 4H), 7.81–7.83 (m, 1H), 8.01 (d, 1H, *J*= 6.9 Hz), 8.31 (s, 1H), 8.93 ppm (s, 1H). ESI^+/MS *m/z* 433 $(M+Na)^+$, ESI^+/MS/MS *m/z* 433 (100), 324 (30), 298 (70). Anal. calcd for $C_{22}H_{26}N_4O_4$: C 64.37, H 6.38, N 13.65, found: C 64.49, H 6.34, N 13.34.

(2*R*)-2-[3-(3-Hydroxyphenyl)ureido]-*N*-(2-oxoazepan-3-yl)-3-phenylpropanamide ((2*R*)-43). Eluted with $CHCl_3$/MeOH 19:1. 41% Yield. ^{1}H NMR (500 MHz, [D6]DMSO): δ= 1.12–1.41 (m, 2H), 1.56–1.88 (m, 4H), 2.77–2.83 (m, 1H), 2.96 (dd, 1H, *J*= 13.7, 5.4 Hz), 3.01–3.06 (m, 1H), 3.12–3.20 (m, 1H), 4.34–4.38 (m, 1H), 4.48–4.56 (m, 1H), 6.21–6.29 (m, 2H), 6.64 (d, 1H, *J*= 7.8 Hz), 6.90–6.95 (m, 2H), 7.15–7.20 (m, 1H), 7.21–7.26 (m, 4H), 7.80–7.83 (m, 1H), 7.97–8.08 (m, 1H), 8.52 (d, 1H, *J*= 3.9 Hz), 9.17 ppm (s, 1H). ESI/MS *m/z* 409 $(M-H)^-$, ESI-MS/MS *m/z* 274 (70), 182 (86), 134 (100). Anal. calcd for $C_{22}H_{26}N_4O_4$: C 64.37, H 6.38, N 13.65, found: C 64.65, H 6.52, N 13.48.

(2*S*)-2-[3-(4-Hydroxyphenyl)ureido]-*N*-(2-oxoazepan-3-yl)-3-phenylpropanamide ((2*S*)-44). Eluted with $CHCl_3$/MeOH 19:1. ^{1}H NMR (500 MHz, [D6]DMSO): δ= 1.12–1.39 (m, 2H), 1.55–1.87 (m, 4H), 2.77–2.82 (m, 1H), 2.94 (dd, 1H, *J*= 13.7, 5.4 Hz), 3.01–3.04 (m, 1H), 3.11–3.19 (m, 1H), 4.32–4.37 (m, 1H), 4.45–4.53 (m, 1H), 6.11–6.18 (m, 1H), 6.58 (d, 2H, *J*= 8.8 Hz), 7.04–7.08 (m, 2H), 7.15–7.18 (m, 1H), 7.20–7.27 (m, 4H), 7.81–7.84 (m, 1H), 7.94–8.03 (m, 1H), 8.28 (s, 1H), 8.92 ppm (s, 1H). 74% Yield. ESI^+/MS *m/z* 433 $(M+Na)^+$, ESI^+/MS/MS *m/z* 433 (100), 324 (25), 298 (62). Anal. calcd for $C_{22}H_{26}N_4O_4$: C 64.37, H 6.38, N 13.65, found: C 64.52, H 6.29, N 13.56.

(*S*)-2-[3-(3-Hydroxyphenyl)ureido]-*N*-(2-oxoazepan-3-yl)-3-phenylpropanamide ((2*S*)-45). Eluted with $CHCl_3$/MeOH 19:1. 28% Yield. ^{1}H NMR (500 MHz, [D6]DMSO): δ= 1.12–1.41 (m, 2H), 1.56–1.88 (m, 4H), 2.77–2.83 (m, 1H), 2.96 (dd, 1H, *J*= 13.7, 5.4 Hz), 3.01–3.06 (m, 1H), 3.12–3.20 (m, 1H), 4.34–4.38 (m, 1H), 4.48–4.56 (m, 1H), 6.21–6.29 (m, 2H), 6.64 (d, 1H, *J*= 7.8 Hz), 6.90–6.95 (m, 2H), 7.15–7.20 (m, 1H), 7.21–7.26 (m, 4H), 7.80–7.83 (m, 1H), 7.97–8.08 (m, 1H), 8.52 (d, 1H, *J*= 3.9 Hz), 9.17 ppm (s, 1H). ESI/MS *m/z* 409 $(M-H)^-$, ESI-MS/MS *m/z* 274 (70), 182 (86), 134 (100). Anal. calcd for $C_{22}H_{26}N_4O_4$: C 64.37, H 6.38, N 13.65, found: C 64.39, H 6.35, N 13.59.